VIFOR PHARMA TO PROPOSE JACQUES THEURILLAT AS BOARD MEMBER
March 29, 2018 00:53 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Jacques Theurillat to be proposed...
VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN
March 27, 2018 00:55 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Vifor Pharma gives Zeria...
VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE
March 15, 2018 01:54 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
IN 2017 VIFOR PHARMA RECORDED A...
VIFOR PHARMA FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL
February 08, 2018 00:58 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
VIFOR PHARMA ANNOUNCED TODAY THAT...
AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY
January 04, 2018 00:58 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Conditional marketing authorization...
VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA
January 04, 2018 00:53 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Klicken Sie hier für Deutsch ...
THIRD GLOBAL IRON DEFICIENCY DAY TO RAISE AWARENESS OF THE SYMPTOMS OF IRON DEFICIENCY
November 23, 2017 00:59 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Iron Deficiency Day takes place...
VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF MIRCERA® IN THE US
September 27, 2017 00:56 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Additional Mircera® volume will...
VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE
August 08, 2017 00:55 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Strong financial performance in H1...
EUROPEAN COMMISSION APPROVES MARKETING AUTHORISATION FOR VELTASSA®
July 21, 2017 00:58 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Veltassa® approved for marketing...